

Immunohistochemical evaluation of actin expression in basal cell carcinoma and oral squamous cell carcinoma

Nadia S. Yass, B.D.S., M.Sc., PhD. (Oral Pathology) ⁽¹⁾

Seta A. Sarkis, B.D.S., M.Sc., PhD. (Oral Pathology) ⁽²⁾

Ban F. AL Drobie ,B.D.S.,M.SC.,PhD.(Oral Pathology)⁽³⁾

Ahlam H. Majeed, B.D.S., MSc. (Oral Pathology) ⁽⁴⁾

Key words

Basal Cell Carcinoma, Oral Squamous Cell Carcinoma, α -SMA

Abstract

Background: Basal cell carcinomas (BCCs) are generally slow-growing tumours. They have been classified as aggressive (A-BCC) and non-aggressive (NA-BCC). Oral squamous cell carcinoma (OSCC) is a major cause of cancer morbidity worldwide, this is due to the characteristics of invasion. The microenvironment or stroma of neoplastic tissues plays an active role in tumour progression. Trans-differentiation of fibroblast to myofibroblast is a crucial and early event in tumorigenesis. Alterations of contractile tension generated by the actin-myosin complex are of central importance in the development of the phenotype of morphologically transformed neoplastic cells with invasive behavior. Actin is the predominant component of contractile microfilament and it may be associated with increase contractility and invasiveness of tumour cells.

Objective: This study aimed to investigate the presence of myofibroblasts in the stroma of basal cell carcinoma and oral squamous cell carcinoma, evaluated by the immunohistochemical expression of actin.

Materials and methods: Twenty four formalin-fixed, paraffin-embedded tissue blocks (14 cases basal cell carcinoma, 10 cases oral squamous cell carcinoma) were included in this study. An immunohistochemical analysis was performed using anti α -smooth muscle actin (α -SMA) monoclonal antibody.

Results: All cases of OSCC, BCC and normal oral mucosa showed positive reaction of actin in the smooth muscles surrounding blood and lymphatic vessels. All OSCC and BCC cases demonstrated stromal immunostaining for actin with different scores indicating the presence of myofibroblasts. There were no myofibroblasts in the stroma of normal mucosa indicated by negative α -SMA expression in it.

Conclusions: Immunohistochemical examination of BCC and OSCC for this marker may help clinicians in predicting tumour behaviour.

(1) Assistant Professor, Department of Oral Pathology, College of Dentistry, University of Baghdad.

(2) Assistant Professor, Department of Oral Pathology, College of Dentistry, University of Baghdad.

(3) Lecturer, Department of Oral Pathology, College of Dentistry, University of Baghdad

(4) Professor, Department of Oral Pathology, College of Dentistry, University of Baghdad.

Introduction

Basal cell carcinoma (BCC) is the most commonly diagnosed malignant skin tumour in white races ^(1, 2). BCCs are generally slow-growing tumours that require months to years to double in size, despite high mitotic rate ^(2,3,4). BCC has

been classified as aggressive (A-BCC) and non-aggressive (NA-BCC) by well-described clinicopathological criteria. Immunohistochemical markers such as actin have received significant interest in connection with BCC. Actin is the predominant component of contractile microfilaments⁽⁵⁾. Alpha-smooth muscle actin (α -SMA) is found exclusively in contractile muscle cells, myoepithelial cells and myofibroblasts^(5, 6, 7). It has been suggested that an altered expression of α -SMA in BCC might be predictive of aggressive invasion^(5, 6).

Oral squamous cell carcinoma (OSCC) is a major cause of cancer morbidity worldwide⁽⁷⁾. The 5-year survival rate for OSCC is about 40% and has improved only poorly over the past decades⁽⁸⁾. OSCC is highly correlated with metastasis and treatment depends on the anatomical site of the disease^(9,10). Conventional treatment includes surgery and / or radiation and / or chemotherapy is associated with significant morbidity, affects speech, swallowing and overall quality of life. Despite these interventions a recurrence of the disease is observed in about 50% and is associated with high rates of mortality. During the last years, important advances have been made in understanding carcinogenesis, resulting in improved diagnosis and treatment^(11, 12).

One of the characteristics of malignancy is invasion. Cytoskeletal reorganizations, especially alterations of contractile tension generated by the actin–myosin complex, are of central importance in the development of the phenotype of morphologically transformed neoplastic cells with invasive behavior. Actin may be associated with increased contractility and invasiveness of tumour cells, and have been identified in infiltrative basal cell carcinoma^(13, 14, 15). However, the number of studies evaluates the role of myofibroblasts in OSCC remained limited.

The present study investigated the presence of myofibroblasts in the stroma of oral squamous cell carcinoma and basal cell carcinoma evaluated by the immunoreactivity of actin in them.

MATERIALS AND ETHODS:

The study was conducted on twenty four formalin-fixed paraffin embedded tissue blocks of which, 14 cases were diagnosed as basal cell carcinoma obtained from the archives of Al-Shaheed Ghazi Hospital, Teaching Laboratory Department/ Baghdad Medical City/, and 10 cases were diagnosed as squamous cell carcinoma, obtained from the archives of the department of Oral & maxillofacial Pathology/ College of Dentistry/ Baghdad University.

Tumour histology was reviewed blindly by two pathologists, and representative paraffin blocks were selected. Data concerning patients' age, sex, clinical presentation and tumours site were obtained from the associated surgical reports.

Immunohistochemistry was performed on 4 μ m, formalin-fixed, paraffin-embedded serial sections of tumour blocks using anti α - SMA monoclonal antibody (US Biological/Catalogue No A0760-26).

Negative and Positive tissue controls were included into each immunohistochemical run. Positive control for SMA was obtained from colon tissue that had acute appendicitis according to the manufacturer (Fig. 1).

Normal oral mucosa was obtained from patients undergoing tooth extraction for orthodontic purposes who have no sign of inflammatory gingival or periodontal disease to compare the immunoreaction of actin to that of the studied lesions.

Slides were put in hot air oven at 65°C overnight. Sections were sequentially dewaxed and rehydrated through a series of xylene, graded alcohol and water immersion steps. Then endogenous peroxidase activity was blocked followed by blocking the non- specific staining. Anti SMA monoclonal antibody (100 ml) at a dilution (1-200) was applied for each section. The samples were then incubated at 4°C overnight in a humid chamber. After washing with phosphate buffered solution (PBS), secondary Ab was applied to the sections, incubated and rinsed with a stream of PBS. Primary Ab was visualized with diaminobenzidine (DAB) chromogen. Sections were counterstained

with Mayer's hematoxyline for 30 seconds, dehydrated and mounted.

SMA was subjectively scored, according to the extent of stromal positivity Deihimy et al, 2006⁽¹⁶⁾ as follows:

- 0: Negative or non-reactive.
- 1- +: Scattered spotty staining.
- 2- ++: 25% positive tumour cell.
- 3- +++: 25-50% positive tumour cell.
- 4- ++++: More than 50% positive tumour cell.

RESULTS:

Out of 14 cases of BCC, 12 were males and 2 were females, their age was from (30-83) years. Clinically the lesions ranged from small papular lesion to big nodular lesions, some with crustation or appeared as ulcerated areas. These lesions were scattered on the skin of the face and scalp.

Out of 10 cases of SCC, 3 were females and 7 were males with an age range of (35-75) years. Four of the cases were located on the tongue; 3 on the mandibular area; 2 on the maxilla and one case on the buccal mucosa.

Histology and immunohistochemistry:

The histological grading of OSCC cases was as follows: - 6 cases were well differentiated SCC, 3 cases were moderately differentiated and one case was poorly differentiated SCC.

Blood vessels present within the connective tissue of the immunostained sections served as positive internal control. All cases of SCC, BCC and normal oral mucosa showed positive reaction of actin in the stromal smooth muscles surrounding blood and lymphatic vessels (Fig.2, 3, 5, 6). All SCC and BCC cases demonstrated stromal immunostaining for actin with different scores indicating the presence of myofibroblasts (Fig.3,4, 5, 6). There were no myofibroblasts in the stroma of normal mucosa indicated by negative α -SMA immunostaining (Fig.2). Regarding the immunostaining of the tumour cell itself, out of ten cases of SCC, only two cases showed nuclear staining for actin that is score 1. While out of fourteen

cases of BCC, positive tumour cells were recorded only in three cases, one with score 1, one with score 2 and the third with score 4.

DISCUSSION

Basal cell carcinoma and squamous cell carcinoma are two of the most common tumours seen by pathologists. Interestingly, smooth muscle actin (SMA) has been found to be expressed in a significant number of basal cell carcinomas of the skin (13 of 17 cases in one study)⁽¹⁷⁾. Moreover, stromal (SMA) expression was found to be restricted to the aggressive BCCs, in addition, a significant difference of this expression was found between aggressive and non-aggressive tumours, these findings suggested that stromal (SMA) expression is an accurate and reliable marker of aggressiveness in BCC^(18,19)

In this study statistical analysis was not performed because the study concerned to demonstrate the presence or absence of myofibroblasts in the stroma of both BCC and OSCC samples indicated by actin immunoexpression. Indeed, in the current study SMA reactivity was observed in a number of basal cell carcinomas which have been stained (both tumour cell expression (3 cases) and stromal α -SMA expression (all cases)), although the frequency of reactivity is not as high in our hands as in some published series. It has been reported that actin within the stroma surrounding BCC nests is a marker for myofibroblasts that play a significant role in invasion, as they secrete stromolysin-3, a metalloproteinase that degrades the stromal matrix^(20, 21). Degradation of the stromal matrix may enhance the stromal-tumour communication that is essential for invasion. Although the pathophysiologic

mechanism responsible for the myofibroblastic reaction is obscure, it has been proposed that the induction of cytokines from BCC cells (such as basic fibroblast growth factor) may be responsible for stromal α -SMA expression. The same BCC-derived cytokines that induce the stromal myofibroblastic response have an autocrine effect on the individual BCC cells, increasing tumoural actin synthesis and leading to enhanced cellular motility and invasion^(22, 23).

An increased expression of stromal α -SMA might reflect increased aggressiveness in BCC and immunohistochemical examination of BCCs for this marker may help clinicians in predicting tumour behaviour.

It has become increasingly apparent, however, that the 'normal' components of the tumour stroma (including fibroblasts, inflammatory cells, and endothelial cells) play an important role in promoting tumour progression^(24, 25). Many types of solid tumours appeared to contain smooth muscle actin positive myofibroblasts ('activated' fibroblasts, peritumour fibroblasts, carcinoma-associated fibroblasts) within the stroma. Myofibroblastic trans-differentiation is modulated mainly through TGF- β 1 signaling and may be induced in a number of different cell types, including fibroblasts, pericytes, circulating fibrocytes, and mesenchymal cells⁽²⁵⁾.

Additionally, in recent years the concept of epithelial mesenchymal transition (EMT) has received much attention, with suggestions that apparent stromal cells actually may be derived from epithelial tumour cells^(26, 27, 28). Functional assays showed that OSCC cells can promote fibroblast-to-myofibroblast trans-differentiation through α v β 6-dependent activation of TGF- β 1 and that myofibroblasts, in turn, promote OSCC invasion⁽²⁸⁾. High Myofibroblasts have been reported to be associated with poor prognosis in several carcinoma types^(29, 30). It has been shown previously that myofibroblasts promote the invasion of OSCC cells and that aggressive variants of basal cell carcinoma of the skin contain a prominent, myofibroblastic stroma, which modulates keratinocyte motility through secretion of hepatocyte growth factor (HGF)⁽³¹⁾.

Moreover, the strongest independent risk factor of early OSCC death has been reported to be a feature of the stroma rather than tumour cells and the high stromal SMA expression produced the highest hazard ratio and likelihood ratio of any feature examined, and were strongly associated with mortality, regardless of disease stage⁽³²⁾. Furthermore Stromal SMA expression revealed to be used to identify aggressive OSCC, regardless of disease stage, and might be important for the treatment and follow-up of OSCC patients.⁽³³⁾




Figure 1: Positive actin immunostaining in acute appendicitis (positive control) (x200)




Figure 2: Positive actin immunostaining of the smooth muscles surrounding vascular and lymphatic vessels in normal oral mucosa (X400)




Figure 3: Positive immunostaining of actin in the stroma as well as the smooth muscles surrounding vascular and lymphatic vessels in well differentiated SCC (X200)




Figure 4: Positive stromal actin immunostaining in well differentiated SCC (X200)



Figure 5: Positive immunostaining of actin in the stroma as well as the smooth muscles surrounding vascular and lymphatic vessels in BCC (X200)

References

1. Wang WJ, Huang JY, Wong CK, Chang YT. A study of secondary cutaneous amyloidosis in basal cell carcinoma in Chinese patients: lack of correlation with bcl-2 and p53 protein expression. *Arch Dermatol Res* 2000; 292:379 -383.
2. Gordon PM, Cox NH, Paterson WD, Lawrence CM. Basal cell carcinoma: are early appointments justifiable? *Br J Dermatol* 2000; 142: 446 -448.
3. Haake AR, Polakowska RR. Cell death by apoptosis in epidermal biology. *J Invest Dermatol* 1993; 101: 107 - 112.
4. Christian MM, Moy RL, Wagner RF, Yen-Moore A. A correlation of a smooth muscle actin and invasion in micronodular basal cell carcinoma. *Dermatol Surg* 2001; 27: 441 -445.
5. Tsukamoto H, Hayashibe K, Mishima Y, Ichihashi M. The altered expression of a smooth muscle actin in basal cell epithelioma and its surrounding stroma: with special reference to proliferating cell antigen expression and adenoid differentiation. *Br J Dermatol* 1994; 130: 189 -194
6. De Rosa G, Barra E, Guarino M, Staibano S, Donofrio V, Boscaino A. Fibronectin, laminin, type IV collagen distribution, and myofibroblastic stromal reaction in aggressive and non-aggressive basal cell carcinoma. *Am J Dermatopathol* 1994; 16: 258 -267.
7. Ferlay J, Bray F, Pissani P. Cancer incidence, Mortality and Prevalence Worldwide, IARC Cancer Base 2001 Version 1.0. No. 5 .
8. Jemal A, Siegel R, Ward E. Cancer statistics. *Cancer J Clin* 2007; 57: 43-66.
9. Barnes L, Verbin R, Guggenheimer J. Cancer of the oral cavity and oropharynx. In: Barnes L, ed. *Surgical pathology of the head and neck*, 2nd edn. New York: Marcel Dekker, 2001; 370-438.
10. Schwartz GJ, Metha RH, Wenig BL. Salvage treatment for recurrent squamous cell carcinoma of the oral cavity. *Head Neck* 2000; 22: 34-41.
11. Nagpal KJ, Das RB. Oral cancer: reviewing the present understanding of its molecular mechanism and exploring the future directions for its effective management. *Oral Oncol* 2003; 39: 213-21.
12. Thurnher D, Kornfehl J, Burian M. Ifosfamide and mitoxantrone in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. *Anticancer Drugs* 2001; 12: 121-208.
13. Christian MM, Moy RL, Wagner RF. A correlation of alpha-smooth muscle actin and invasion in micronodular basal cell carcinoma. *Dermatol Surg* 2001; 27: 441-445.
14. Law AM, Oliveri CV, Pacheco-Quinto X. Actin expression in purely nodular versus nodular-infiltrative basal cell carcinoma. *J Cutan Pathol* 2003; 30: 232-236.
15. Lee MW, Ahn SJ, Choi JH. Actin and calponin expression in basal cell carcinoma. *Br J Dermatol* 2004; 151: 934-936.
16. Deihimi P, Makazooni P, Torabinia N. Study of myoepithelial cell markers in pleomorphic adenoma and mucoepidermoid carcinoma of salivary gland tumours. *Dental Research Journal* 2006; 3:(2)
17. Varma M. Expression of smooth muscle antigens in basal cell carcinomas of skin. *Mod Pathol* 1999; 12:(1)
18. Adegboyega, P.A. Rodriguez, S. McLarty, J. Stromal expression of actin is a marker of aggressiveness in basal cell carcinoma. *Human Pathology* 2010; 41; 8, 1128-1137. (ivsl)
19. Bozdogan, O. , Erkek, E., Atasoy, P., Kocak, M., et al. Bcl-2-related Proteins, alpha-Smooth Muscle Actin and Amyloid Deposits in Aggressive and non-Aggressive Basal Cell Carcinomas. *Acta Dermatovenereologica* 2002 ; 82 : 6 , 423-427. (ivsl)
20. De Wever O, Demetter P, Mareel M, et al. Stromal myofibroblasts are drivers of invasive cancer growth. *Int J Cancer* 2008; 123: 2229-2238.
21. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. *Nature* 2001; 411: 375-379.
22. Thurnher D, Turhani D, Pelzmann M, et al. Betulinic acid: a new cytotoxic compound against malignant head and neck cancer cells. *Head Neck* 2003; 9: 732-40
23. Thurnher D, Barkoeva M, Schutz G. Non-steroidal anti-inflammatory drugs induce apoptosis in head and neck cancer cell lines. *Acta Otolaryngol* 2001; 121: 957-62.
24. Erovic BM, Pelzmann M, Turhani D, et al. Differential expression pattern of cyclooxygenase-1 and -2 in head and neck squamous cell carcinoma. *Acta Otolaryngol* 2003; 123: 950-3.
25. Lewis MP, Lygoe K, Nystrom ML, et al. SCC-derived TGF-β1 promotes myofibroblast differentiation and modulates scatter factor-dependent tumour invasion. *Br J Cancer* 2004; 90: 822-832.
26. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. *Cell Res* 2009; 19: 156-172.
27. Radisky DC, Kenny PA, Bissell MJ. Fibrosis and cancer: do myofibroblasts come also from

- epithelial cells via EMT? *J Cell Biochem* 2007; 101: 830–839.
28. Marsh D, Dickinson S, Neill GW, *et al.* Alpha6 integrin promotes invasion of basal cell carcinoma through stromal modulation. *Cancer Res* 2008; 68: 3295–3303.
29. Tsujino T, Seshimo I, Yamamoto H, *et al.* Stromal myofibroblasts predict disease recurrence for colorectal cancer. *Clin Cancer Res* 2007; 13: 2082–2090.
30. Surowiak P, Murawa D, Materna V, *et al.* Occurrence of stromal myofibroblasts in the invasive ductal breast cancer tissue is an unfavourable prognostic factor. *Anti Cancer Res* 2007; 27: 2917–2924.
31. Kitano Y. Distribution of actin filament in human malignant keratinocytes. *Cell Biol Int Rep* 1988; 12: 189–194
32. Kellermann MG, Sobral LM, da Silva SD, *et al.* Myofibroblasts in the stroma of oral squamous cell carcinoma are associated with poor prognosis. *Histopathology* 2007; 51: 849–853.
33. Marsh D., Suchak K., Moutasim KA, Vallath S, Hopper C, Jerjes W, Upile T, Kalavrezos N, Violette Sh M, Weinreb PH, Chester KA, Chana J S, Marshall J F, Hart IR, Hackshaw AK, Piper K and Thomas GJ. Stromal features are predictive of disease mortality in oral cancer patients. *J Pathol* 2011; 223: 470–481